Amedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance

Amedisys (NASDAQ: AMED) reported Q1 EPS of $1.11, $0.21 better than the analyst estimate of $0.90. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $460.61 million.

GUIDANCE:

Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.02. Amedisys sees FY2019 revenue of $1.94-1.98 billion, versus the consensus of $1.96 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
• Texas Capital Bancshares (TCBI) Misses Q1 EPS by 12c
• Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip